The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma
Annals of Hematology, 05/09/2012
Lin TL et al. – The results showed that patients with younger age or better performance status received more intensive treatment. The treatment regimen was not different between patients with lower and higher Charlson comorbidity index (CCI). Rituximab–containing regimens improved the outcome of elderly patients with diffuse large B cell lymphoma (DLBCL).